[Urological aspects in patients with liver cirrhosis]

Der Urologe. Ausg. A
|October 17, 2015
PubMed

Insights

Liver cirrhosis (LC) patients often have urological issues, complicating diagnosis and treatment due to poor health. Urologists must adapt care, considering altered PSA values and disease severity for safe interventions in this growing patient group.

Area of Science:

  • Urology
  • Hepatology
  • Internal Medicine

Background:

  • Patients with liver cirrhosis (LC) exhibit higher comorbidity and urological disease prevalence.
  • Short life expectancy and poor general health in LC patients complicate medical interventions.
  • Increasing LC prevalence necessitates greater attention from urological practices.

Purpose of the Study:

  • To highlight diagnostic and therapeutic challenges of urological diseases in liver cirrhosis patients.
  • To emphasize the need for adjusted prostate-specific antigen (PSA) monitoring in LC patients.
  • To discuss management strategies for bladder dysfunction, infections, hypogonadism, and malignancies in LC.

Main Methods:

  • Review of existing literature on urological conditions in liver cirrhosis.
  • Analysis of diagnostic and therapeutic considerations specific to LC patients.
  • Evaluation of surgical intervention safety based on LC severity.

Main Results:

  • LC patients present unique challenges in diagnosing and treating urological conditions.
  • Altered baseline PSA values in LC require careful consideration for prostate cancer screening.
  • Treatment decisions, especially surgical interventions, must be tailored to the individual's LC severity and overall health status.

Conclusions:

  • The rising global prevalence of liver cirrhosis presents significant challenges for urological care.
  • Urological diagnosis and therapy in LC patients are frequently complicated by their compromised health status.
  • Personalized and cautious approaches are essential for managing urological conditions in this vulnerable population.
Abstract

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
761
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
335
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
345
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
957